SPRY Stock Summary and Trading Ideas (Ars Pharmaceuticals | NASDAQ:SPRY)

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Ars Pharmaceuticals trades on the NASDAQ stock market under the symbol SPRY.

As of December 18, 2025, SPRY stock price declined to $9.82 with 792,788 million shares trading.

SPRY has a beta of 0.35, meaning it tends to be less sensitive to market movements. SPRY has a correlation of 0.01 to the broad based SPY ETF.

SPRY has a market cap of $970.47 million. This is considered a Small Cap stock.

Last quarter Ars Pharmaceuticals reported $33 million in Revenue and -$.52 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.05.

In the last 3 years, SPRY traded as high as $18.90 and as low as $2.55.

The top ETF exchange traded funds that SPRY belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

SPRY has underperformed the market in the last year with a return of -16.5%, while the SPY ETF gained +13.1%. In the last 3 month period, SPRY fell short of the market, returning +2.6%, while SPY returned +2.9%. However, in the most recent 2 weeks SPRY has outperformed the stock market by returning +2.8%, while SPY returned -1.1%.

SPRY support price is $9.52 and resistance is $10.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRY shares will trade within this expected range on the day.